A meta-analysis of nine Chinese studies found that mood stabilizer medications significantly reduced self-injury severity, anxiety, and depression in adolescents with nonsuicidal self-injury (NSSI), with greater reductions when mood stabilizers were added to standard care versus standard care alone .
Nonsuicidal self-injury, defined as deliberate and repeated damage to body tissue without intent to die, affects a meaningful subset of adolescents globally. Understanding which treatments reduce this behavior matters because NSSI often co-occurs with depression and anxiety, and current treatment options remain limited. This systematic review and meta-analysis synthesized data from nine studies conducted in China (four controlled trials comparing mood stabilizers plus standard care versus standard care alone, and five before-after studies) to evaluate whether mood-stabilizing medications help reduce self-injury in depressed adolescents.
The researchers found consistent reductions across multiple measured outcomes when adolescents received mood stabilizers. Anxiety severity decreased significantly in the treatment groups, as did depression scores. Critically, impulsivity and the severity of self-injury behavior itself both showed marked improvement. The studies also tracked binary outcomes: treatment response rates were significantly higher in groups receiving mood stabilizers compared to control groups, and the incidence of self-injury episodes was substantially reduced. These findings held even when comparing medication-treated groups directly against standard care without mood stabilizers, suggesting an additive benefit rather than a placebo effect.
What distinguishes this meta-analysis is its focus on mood stabilization as a potential mechanism independent of mood improvement alone. The authors note that mood stabilizers may work through multiple pathways: they reduce affective symptoms like depression and anxiety, but they may also directly target impulsivity and behavioral control circuits. This distinction matters because some adolescents with NSSI continue the behavior even after depression improves if underlying impulsivity remains high. The review suggests that the mood-stabilizing effect itself, rather than antidepressant properties, may be the critical therapeutic element for reducing self-injury.
The evidence base, however, comes entirely from Chinese populations and healthcare settings. The studies varied in their specific mood stabilizer agents (the search included lithium, valproate, carbamazepine, oxcarbazepine, lamotrigine, and some antipsychotics), which means the findings represent a class effect rather than a single agent. The nine included studies represent moderate methodological diversity, with some using randomized designs and others using pre-post comparisons, affecting overall certainty.
If you are an adolescent experiencing self-injury or a parent considering treatment options: this analysis suggests mood stabilizers warrant discussion with a psychiatrist, particularly if depression and anxiety co-occur with self-injury. The evidence is strongest when combined with standard care (psychotherapy, safety planning) rather than as a standalone treatment. Note that this research reflects Chinese clinical populations and may not directly translate to other healthcare contexts due to differences in diagnostic criteria, medication prescribing patterns, and supportive care access.
The mechanism distinction highlighted here is worth understanding: mood stabilizers may help not just by treating depression, but by reducing impulsivity itself. This could mean improved outcomes even if mood symptoms seem stable.
If you are a clinician: the evidence supports considering mood stabilizer augmentation when adolescents with depression present with self-injury behavior, particularly if impulsivity is prominent. The class of agents studied is broad, suggesting flexibility in agent selection based on individual tolerability and comorbidity profiles.
| Parameter | Details |
|---|---|
| Study type | Systematic review and meta-analysis |
| Included studies | 9 studies from Chinese databases (4 RCTs, 5 before-after designs) |
| Population | Adolescents with nonsuicidal self-injury and depression in China |
| Intervention | Mood stabilizers (lithium, valproate, carbamazepine, oxcarbazepine, lamotrigine, antipsychotics) |
| Comparison | Standard care (psychotherapy) with or without mood stabilizers |
| Primary outcomes | Severity of anxiety, depression, impulsivity, self-injury; treatment response rate; incidence of self-injury |
| Key finding | Significant reductions in anxiety, depression, impulsivity, and self-injury severity with mood stabilizers; greater reductions when added to standard care |
| Evidence tier | A tier (systematic review/meta-analysis) |
| Publication | The Journal of Clinical Psychiatry |
| PubMed ID | 42159376 |
Meta-analysis: Systematic Review and Meta-Analysis of Mood Stabilizers in the Treatment of Adolescent Patients With Nonsuicidal Self-Injury in China. The Journal of Clinical Psychiatry. PubMed: 42159376
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.